Clinical trials: Cancer of Gastrointestinal Tract
Collection of Real-world Data in a Single Institute
Outcome of GI Cancer in NCKUH
Alimentary tract cancer patients treated at National Cheng Kung University Hospital during 2013/01/01 to 2020/12/31 were reviewed.
- Trial name
- NCT05700188
- Where
- 2 sites in Taiwan
- Volunteers
- 730 people
- Sponsor
- National Health Research Institutes, Taiwan
Early Detection of Cancer
A Questionnaire for Endoscopic Prediction Improvement of Gastrointestinal Cancer
Despite improvements in a range of chemo, radio and surgical therapies, the overall survival at 5 years from gastrointestinal cancer remains poor.
- Trial name
- NCT04071431
- Testing
- Result masking
- Where
- China
- Volunteers
- 34,906 people, healthy volunteers welcome
- Sponsor
- Yanqing Li
Healthy Volunteers, Liver Cancer
4D-MRI for Precision Medicine
The purpose of this study is to develop new ways to make medical images of the lungs and liver of adults using a technique called four-dimensional magnetic resonance imaging (4D-MRI).
- Conditions
- Healthy Volunteers, Liver Cancer, Lung Cancer
- Trial name
- NCT04657042
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Lung Cancer, Esophageal Cancer
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
At present, the treatment methods for recurrent cancers are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent lung cancer/ esophageal cancer / cervical cancer, but the clinical…
- Conditions
- Lung Cancer, Esophageal Cancer, Cervical Cancer
- Trial name
- NCT06232083
- Testing
- PLDR+Cardunizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Colon Cancer, Lung Cancer
Predictive Genetic Risk Assessment Trial
This proof-of-principle clinical trial at Mayo Clinic studies how patients and their physicians understand and utilize predictive genetic risk assessment.
- Conditions
- Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2
- Trial name
- PGT (NCT00782366)
- Testing
- SNP analysis
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Cancer, Thoracic Neoplasms
Improving Cancer On-treatment Symptom Management
Patient-reported outcome measures (PROMs) is an umbrella term that refers to any report on a health status measure that is reported directly by the patient, without the influence of clinicians or anyone else.
- Conditions
- Cancer, Thoracic Neoplasms, Gastrointestinal Cancer, Lung Cancer
- Trial name
- IMPROVE (NCT04589247)
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Biliary Tract Cancer
Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
eligible subjects will receive treatment beginning on Day 1 of each 3-week dosing cycle for pembrolizumab. Treatment with pembrolizumab will continue until documented disease progression, unacceptable adverse…
- Trial name
- NCT03110328
- Testing
- MK3475
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Biliary Tract Neoplasms
Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer
Malignant tumors of the biliary system are highly invasive and malignant with an increasing incidence rate. Comprehensive drug therapy is the main treatment for advanced biliary tract tumors, yet the current gemcitabine plus…
- Trial name
- NCT07890311
- Testing
- MRG003 (Becotatug Vedotin)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangmen Central Hospital
Cholangiocarcinoma, Adenocarcinoma of Gallbladder
A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC
The primary objective is to investigate the objective response rate in patients receiving GEMOX (gemcitabine plus oxaliplatin) plus cetuximab as first line treatment in advanced or metastatic unresectable BTC biliary tract cancer…
- Trial name
- BTC (NCT01267344)
- Testing
- gemcitabine, oxaliplatin, cetuximab, gemcitabine, oxaliplatin
- Where
- Taiwan
- Volunteers
- 122 people
- Sponsor
- National Health Research Institutes, Taiwan
GI Cancers, Gastrointestinal Cancer
Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis
The primary objective of the study is to determine sleep disturbance and its types among patients with gastrointestinal cancers during the perioperative period (preoperative and in-hospital stay following surgery) by using…
- Trial name
- NCT05044312
- Testing
- Sleeping Disturbances
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Brain Cancer, Head and Neck Cancer
A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery
By utilizing fitness trackers, this study aims to demonstrate that a simple walking program improves patients' ability to tolerate curative concurrent chemoradiotherapy without treatment interruption.
- Conditions
- Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer
- Trial name
- NCT03115398
- Testing
- Pedometer-based Walking Program
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- Montefiore Medical Center
Carcinomas, Squamous Cell, Dysphagia
A Pilot Study of Acupuncture Treatment for Dysphagia
The current standard of care for advanced HNC is concurrent chemoradiation therapy (CRT), which has led to increased survival rates, but with significant acute and long-term toxicities.
- Trial name
- NCT00797732
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Digestive Cancers, Bile Duct Cancer
Spanish Registry of Digestive Tumours RETUD
The aim of this observational study is to assess the current state of digestive tumours in Spain. By doing so, it seeks to enhance the quality of care, optimize the diagnosis and treatment of digestive tumours, and identify…
- Conditions
- Digestive Cancers, Bile Duct Cancer, Hepatocellular Cancer (HCC), Colorectal Cancer (CRC)
- Trial name
- RETUD (NCT06711211)
- Where
- Spain
- Volunteers
- 20,000 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select…
- Trial name
- NCT04943900
- Testing
- BMS-986416, Nivolumab
- Where
- 19 sites in United States, Argentina and 5 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Obesity, Weight Loss
Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesity
In the proposed study, we will be evaluating the effects of pylorus sparing antral myotomy alone, without concomitant endoscopic sleeve gastroplasty (ESG), on weight loss for subjects undergoing the procedure with a history of…
- Conditions
- Obesity, Weight Loss, Delayed Gastric Emptying Following Procedure, Obesity, Mild
- Trial name
- BEAM (NCT05713071)
- Testing
- Bariatric Endoscopic Antral Myotomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Anus
Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
This is a multicentric, retrospective, and prospective biomarker study.
- Trial name
- NCT06236464
- Testing
- Multiparameter analysis of each sample
- Where
- 4 sites in Italy
- Volunteers
- 170 people
- Sponsor
- National Cancer Institute, Naples
Non-small Cell Lung Cancer, Colorectal Cancer
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid…
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT05935384
- Testing
- Guardant360
- Where
- United States
- Volunteers
- 470 people
- Sponsor
- Guardant Health, Inc.
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.